CureVac (CVAC)
(Delayed Data from NSDQ)
$2.52 USD
+0.19 (8.15%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.52 0.00 (0.00%) 6:24 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CVAC 2.52 +0.19(8.15%)
Will CVAC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CVAC
Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?
Company News for Jan 11, 2023
Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade
Other News for CVAC
CureVac price target lowered by $4 at UBS, here's why
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Curevac’s Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
CureVac just downgraded at Leerink, here's why